News You Might Have Missed: Jan 16th 2022

The article News You Might Have Missed: Jan 16th 2022 was originally published on Microdose.

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.

Cybin Selects Generalized Anxiety Disorder for DMT Drug CYB-004

Cybin has selected Generalized Anxiety Disorder as the target indication for its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule, CYB004.

CYB004 is the company’s 2nd main drug development program, a novel form of DMT Cybin believes has novel properties for potential therapies. The selection of anxiety disorders differentiates Cybin from other firms developing DMT.

Algernon Pharmaceuticals Announces Plans for 180 Patient Phase 2b Study

Algernon continues to move its programs forward, as it announces plans for a 180 patient, 90-day Phase 2b clinical study of NP-120 (“Ifenprodil”) for chronic cough to begin in Q3 of 2023.

Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist. The decision to advance the study is based on positive data previously reported on July 28, 2022, from Algernon’s Phase 2a study of Idiopathic Pulmonary Fibrosis (IPF) and chronic cough, where Ifenprodil showed positive results.

Enthea Announces Nationwide Rollout: Psychedelic Therapy as Workplace Benefit

The health insurance plan provider announced today its successful $2M seed round raise, led by Tabula Rasa Ventures, the first psychedelic accelerator for early-stage startups. The funds will be used to launch its services into 40 markets across the U.S. next year as well as grow Enthea’s customer base and provider network to further its mission of providing affordability and access to safe and effective psychedelic-assisted therapies for all who can benefit.

PharmaTher Holdings Provides Update for KETARX (Racemic Ketamine) Development Programs and Expected Milestones for 2023

Fabio Chianelli, CEO of PharmaTher: “We have made key development progress in 2022 that paves the way for potential near-term commercialization opportunities with our own racemic ketamine, which we brand as KETARX, for multiple indications in mental health, neurological and pain disorders.”

Company aims to advance clinical development programs of KETARX, including (i) Phase 3 clinical study for Parkinson’s disease; (ii) Phase 2 clinical study with microneedle patch; and (iii) Phase 2 clinical study for Amyotrophic lateral sclerosis.

First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026

Dr. Carol Routledge, Chief Medical and Scientific Officer, said: “IM injection of  SPL026  may  provide  greater  convenience  for  physicians,  as  well  as potentially improve the  treatment experience  for some  patients. This  study seeks to identify a target dose of SPL026, administered via IM injection, that is  well  tolerated  and   delivers  a  consistent  breakthrough   psychedelic experience. By understanding parameters such as the duration and intensity  of the  psychedelic  experience,  we  will  be  able  to  explore  the  potential application of IM SPL026 for treating mental health conditions.”

Revive Therapeutics Closes $4.3 Million Offering

Revive has completed the closing of its previously announced private placement by issuing a  total of 28,676,064 units at a price of $0.15 per Unit, for gross proceeds of $4,301,409.

Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed

Read More